UGT1A and Irinotecan Toxicity: Keeping It in the Family
Authors:
- 20 May 2009
- journal article
- editorial
- Published by American Society of Clinical Oncology (ASCO) in Journal of Clinical Oncology
- Vol. 27 (15) , 2419-2421
Abstract
No abstract availableThis publication has 12 references indexed in Scilit:
- Predictive Role of the UGT1A1, UGT1A7, and UGT1A9 Genetic Variants and Their Haplotypes on the Outcome of Metastatic Colorectal Cancer Patients Treated With Fluorouracil, Leucovorin, and IrinotecanJournal of Clinical Oncology, 2009
- Wild-Type KRAS Is Required for Panitumumab Efficacy in Patients With Metastatic Colorectal CancerJournal of Clinical Oncology, 2008
- Irinotecan Pharmacogenetics: Influence of Pharmacodynamic GenesClinical Cancer Research, 2008
- KRAS Mutations As an Independent Prognostic Factor in Patients With Advanced Colorectal Cancer Treated With CetuximabJournal of Clinical Oncology, 2008
- UGT1A1*28 Genotype and Irinotecan-Induced Neutropenia: Dose MattersJNCI: Journal of the National Cancer Institute, 2007
- Searching for Tissue-Specific Expression Pattern-Linked Nucleotides of UGT1A IsoformsPLOS ONE, 2007
- The Role of UGT1A1*28 Polymorphism in the Pharmacodynamics and Pharmacokinetics of Irinotecan in Patients With Metastatic Colorectal CancerJournal of Clinical Oncology, 2006
- Genetic Variants in the UDP-glucuronosyltransferase 1A1 Gene Predict the Risk of Severe Neutropenia of IrinotecanJournal of Clinical Oncology, 2004
- Irinotecan Dosing: Does the CPT in CPT-11 Stand for “Can’tPredictToxicity”?Journal of Clinical Oncology, 2002
- Racial variability in the UDP-glucuronosyltransferase 1 ( UGT1A1 ) promoter: A balanced polymorphism for regulation of bilirubin metabolism?Proceedings of the National Academy of Sciences, 1998